Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.89M 4.28M 3.95M 3.69M 6.94M 462M 7.1M 47.52M 18.35M 228M 18.35M 17.94M 791M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.21M 10.35M 9.66M 18.19M 1.21B 18.6M 124M 48.06M 597M 48.06M 47.01M 2.07B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
20-04-27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
20-04-08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
20-03-30	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
20-03-30	Motion for Asset Sale Approved for Aradigm Corporation	CI
20-03-09	Bidding Procedure Approved for Aradigm Corporation	CI
20-02-20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20-02-20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
19-10-30	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
19-10-21	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19-07-19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

20-06-15	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-04	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-04-13	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	-.--%	-	-	702K
LONZA GROUP AG	+0.94%	+7.83%	-4.50%	+3.17%	46.2B
REVOLUTION MEDICINES, INC.	+2.53%	+12.87%	+408.70%	+613.77%	38.71B
IQVIA HOLDINGS INC.	+0.22%	+14.07%	+21.46%	-13.55%	31.9B
BEONE MEDICINES AG	+2.64%	+5.74%	+18.73%	+60.93%	31.12B
CELLTRION, INC.	+8.02%	+5.23%	+17.67%	+35.36%	23.77B
ASCENDIS PHARMA A/S	+1.17%	+14.84%	-	-	16.2B
MEDPACE HOLDINGS, INC.	-0.22%	+15.61%	+67.84%	+124.23%	15.05B
EUROFINS SCIENTIFIC SE	-1.13%	+7.40%	+12.81%	+20.67%	13.74B
IONIS PHARMACEUTICALS, INC.	-0.65%	+6.50%	+104.56%	+96.59%	13.42B
Average	+1.30%	+10.60%	+80.91%	+117.65%	25.57B
Weighted average by Cap.	+1.68%	+10.07%	+93.03%	+138.65%

	2016	2017
Net sales	195K 171K 158K 147K 277K 18.44M 283K 1.9M 732K 9.1M 732K 716K 31.58M	14.46M 12.67M 11.69M 10.92M 20.55M 1.37B 21.02M 141M 54.32M 675M 54.32M 53.13M 2.34B
Net income	-32.94M -28.84M -26.62M -24.86M -46.8M -3.11B -47.87M -320M -124M -1.54B -124M -121M -5.33B	-10.7M -9.37M -8.65M -8.08M -15.21M -1.01B -15.56M -104M -40.2M -499M -40.2M -39.32M -1.73B
Net Debt	-9.37M -8.21M -7.58M -7.07M -13.32M -886M -13.62M -91.16M -35.19M -437M -35.2M -34.42M -1.52B	7.91M 6.93M 6.4M 5.97M 11.24M 748M 11.5M 76.97M 29.71M 369M 29.72M 29.06M 1.28B

Aradigm Corporation Stock OTC Bulletin Board

Stocks

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile